SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA)
ARNA 99.990.0%Mar 15 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dr.praveen who wrote (595)10/30/2006 12:32:52 PM
From: scaram(o)uche  Read Replies (1) of 2274
 
>> These compounds are currently in lead optimization phase at GlaxoSmithKline <<

Looks like that was an August 2006 update?

biovitrum.com

I would take this as very good news. Mileage will differ.

I've often seen this, but never tracked it down.... may be discussion of specific molecules??.....

J Med Chem. 2006 Jul 13;49(14):4023-34.

5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents.

Nilsson BM.
Biovitrum AB, SE-112 76 Stockholm, Sweden.

(thank you!)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News